David W Boulton

List of Publications by Year
in descending order

94 papers	3,706 citations	136950 32 h-index	138484 58 g-index
94 all docs	94 docs citations	94 times ranked	3829 citing authors

#	Article	IF	Citations
1	Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. Journal of Clinical Pharmacology, 2022, 62, 541-554.	2.0	2
2	Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. British Journal of Clinical Pharmacology, 2022, 88, 1942-1946.	2.4	8
3	Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4â€Mediated Metabolism of Saxagliptin. Journal of Clinical Pharmacology, 2022, 62, 1018-1029.	2.0	6
4	Relationship of Dapagliflozin WithÂSerumÂSodium. JACC: Heart Failure, 2022, 10, 306-318.	4.1	10
5	Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus. Journal of Clinical Pharmacology, 2022, 62, 1227-1235.	2.0	6
6	MO364: Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing With Sodium Zirconium Cyclosilicate. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
7	Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPAâ€HF Study Population: A Mathematical Modeling Analysis. Journal of Clinical Pharmacology, 2021, 61, 636-648.	2.0	9
8	Evaluation of the Pharmacokinetics and Exposureâ€“Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. Clinical Pharmacokinetics, 2021, 60, 517-525.	3.5	6
9	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the <scp>EXSCEL</scp> and <scp>SAVORâ€TIMI</scp> 53 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2021, 23, 1101-1110.	4.4	4
10	Evolving drug regulatory landscape in China: A clinical pharmacology perspective. Clinical and Translational Science, 2021, 14, 1222-1230.	3.1	11
11	Modelâ€Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 108-118.	2.5	11
12	A modelâ€based approach to investigating the relationship between glucoseâ€insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 991-1000.	4.4	5
13	Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study. CKJ: Clinical Kidney Journal, 2021, 14, 1924-1931.	2.9	8
14	Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults. CKJ: Clinical Kidney Journal, 2021, 14, 1808-1816.	2.9	1
15	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. Diabetes, Obesity and Metabolism, 2020, 22, 798-806.	4.4	11
16	A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drugâ€“Drug Interactions with Orally Administered Medications. Clinical Pharmacokinetics, 2020, 59, 447-462.	3.5	50
17	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 142, 1040-1054.	1.6	128
18	Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 76-91.	2.5	8

#	Article	IF	Citations
19	Effect of onceâ€weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the <scp>EXSCEL</scp> trial. Diabetes, Obesity and Metabolism, 2020, 22, 2493-2498.	4.4	26
20	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	7.4	340
21	Differentiating the Sodiumâ€Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 222-229.	2.5	19
22	Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes, Obesity and Metabolism, 2019, 21, 2684-2693.	4.4	28
23	Effects of the sodiumâ€glucose coâ€transporterâ€2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2667-2673.	4.4	73
24	Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects. Clinical Therapeutics, 2019, 41, 1545-1563.	2.5	5
25	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovascular Diabetology, 2019, 18, 138.	6.8	48
26	Quantitative Systems Pharmacology: An Exemplar Modelâ€Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 380-395.	2.5	33
27	Comparison of pharmacokinetics and the exposureâ€“response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus. British Journal of Clinical Pharmacology, 2019, 85, 1820-1828.	2.4	10
28	Modelâ€based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2019, 21, 1381-1387.	4.4	6
29	Urinary glucose excretion after dapagliflozin treatment: An exposureâ€response modelling comparison between Japanese and nonâ€Japanese patients diagnosed with type 1 diabetes mellitus. Diabetes, Obesity and Metabolism, 2019, 21, 829-836.	4.4	6
30	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. Diabetes Care, 2019, 42, 318-326.	8.6	23
31	Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Openâ€Label Randomized Crossover Study. Clinical Pharmacology in Drug Development, 2019, 8, 549-558.	1.6	3
32	Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 876-882.	4.4	18
33	SGLT2 Inhibition Is Predicted to Reduce LV End Diastolic Pressure: A Mathematical Modeling Analysis. FASEB Journal, 2019, 33, 531.17.	0.5	0
34	Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: <scp>A</scp> quantitative assessment using an integrative systems pharmacology model. Diabetes, Obesity and Metabolism, 2018, 20, 2034-2038.	4.4	4
35	Why do <scp>SGLT2</scp> inhibitors reduce heart failure hospitalization? <scp>A</scp> differential volume regulation hypothesis. Diabetes, Obesity and Metabolism, 2018, 20, 479-487.	4.4	336
36	Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. American Journal of Physiology - Renal Physiology, 2018, 315, F1295-F1306.	2.7	46

#	Article	IF	Citations
37	Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. Clinical Pharmacokinetics, 2017, 56, 11-24.	3.5	37
38	Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study. Clinical Therapeutics, 2016, 38, 1890-1899.	2.5	6
39	Bioequivalence and food effect of heat-stressed and nonâ¿¿heat-stressed dapagliflozin 2.5- and 10-mg tablets. International Journal of Pharmaceutics, 2016, 511, 288-295.	5.2	4
40	Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. Antimicrobial Agents and Chemotherapy, 2016, 60, 2782-2789.	3.2	18
41	Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. Clinical Therapeutics, 2016, 38, 99-109.	2.5	11
42	Bioequivalence of saxagliptin/dapagliflozin fixedâ€dose combination tablets compared with coadministration of the individual tablets to healthy subjects. Pharmacology Research and Perspectives, 2015, 3, e00201.	2.4	11
43	Selective Reaction Monitoring of Negative Electrospray Ionization Acetate Adduct Ions for the Bioanalysis of Dapagliflozin in Clinical Studies. Analytical Chemistry, 2015, 87, 3247-3254.	6.5	26
44	Bioequivalence, Food Effect, and Steadyâ€State Assessment of Dapagliflozin/Metformin Extendedâ€release Fixedâ€dose Combination Tablets Relative to Singleâ€component Dapagliflozin and Metformin Extendedâ€release Tablets in Healthy Subjects. Clinical Therapeutics, 2015, 37, 1517-1528.	2.5	14
45	Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. Frontiers in Pharmacology, 2014, 5, 274.	3.5	38
46	Validation of 4Î²â€hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of <scp>CYP3A</scp> activity in healthy subjects. British Journal of Clinical Pharmacology, 2014, 78, 1122-1134.	2.4	73
47	Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2. Clinical Pharmacokinetics, 2014, 53, 17-27.	3.5	180
48	Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2. Regulatory Toxicology and Pharmacology, 2013, 67, 89-97.	2.7	7
49	Bioequivalence of Saxagliptin/Metformin Immediate Release (IR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin IR Tablets in Healthy Adult Subjects. Clinical Drug Investigation, 2013, 33, 365-374.	2.2	13
50	Simultaneous oral therapeutic and intravenous ¹⁴Câ€microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. British Journal of Clinical Pharmacology, 2013, 75, 763-768.	2.4	72
51	The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. British Journal of Clinical Pharmacology, 2013, 76, 432-444.	2.4	98
52	Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes. Diabetes Care, 2013, 36, 3169-3176.	8.6	233
53	Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin. Postgraduate Medicine, 2012, 124, 62-73.	2.0	12
54	A Pharmacometric Approach to Quantify the Impact of Chronic Kidney Disease and Hemodialysis on Systemic Drug Exposure: Application to Saxagliptin. Journal of Clinical Pharmacology, 2012, 52, 126S-33S.	2.0	13

#	Article	IF	Citations
55	Characterization of the In Vitro and In Vivo Metabolism and Disposition and Cytochrome P450 Inhibition/Induction Profile of Saxagliptin in Human. Drug Metabolism and Disposition, 2012, 40, 1345-1356.	3.3	41
56	Biowaiver Approach for Biopharmaceutics Classification System Class 3 Compound Metformin Hydrochloride Using In Silico Modeling. Journal of Pharmaceutical Sciences, 2012, 101, 1773-1782.	3.3	40
57	Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin. Advances in Therapy, 2012, 29, 163-177.	2.9	50
58	Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin. Clinical Pharmacokinetics, 2011, 50, 253-265.	3.5	93
59	Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects. Clinical Drug Investigation, 2011, 31, 619-630.	2.2	19
60	Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. Clinical Pharmacology: Advances and Applications, 2011, 3, 13.	1.2	22
61	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidaseâ€4 inhibitor, in healthy subjects. British Journal of Clinical Pharmacology, 2011, 72, 92-102.	2.4	27
62	The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase. British Journal of Clinical Pharmacology, 2011, 72, 775-786.	2.4	5
63	Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study. Clinical Therapeutics, 2011, 33, 1798-1808.	2.5	75
64	Effect of a Highâ€Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects. Journal of Clinical Pharmacology, 2010, 50, 1211-1216.	2.0	19
65	Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections. Drug Metabolism and Disposition, 2009, 37, 1164-1171.	3.3	89
66	A nonâ€randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steadyâ€state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Human Psychopharmacology, 2009, 24, 145-152.	1.5	18
67	An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 431-439.	1.3	42
68	Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole??in Healthy Subjects and in??Patients??with Schizophrenia. Clinical Pharmacokinetics, 2008, 47, 475-485.	3.5	27
69	Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole. Clinical Pharmacokinetics, 2008, 47, 533-542.	3.5	37
70	Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders. Journal of Clinical Psychopharmacology, 2008, 28, 441-446.	1.4	56
71	Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine. Journal of Clinical Psychopharmacology, 2007, 27, 279-283.	1.4	47
72	Preclinical Pharmacokinetics and Metabolism of BMSâ€214778, a Novel Melatonin Receptor Agonist. Journal of Pharmaceutical Sciences, 2003, 92, 760-772.	3.3	44

#	Article	IF	Citations
73	Validation and application of a high-performance liquid chromatography/tandem mass spectrometry assay for sumatriptan in human plasma. Biomedical Chromatography, 2003, 17, 48-52.	1.7	20
74	One step purification of alpha1-acid glycoprotein from human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 784, 33-38.	2.3	8
75	Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. Food and Chemical Toxicology, 2003, 41, 1199-1201.	3.6	16
76	Great Expectations in Stereochemistry: Focus on Antidepressants. CNS Spectrums, 2002, 7, 28-33.	1.2	17
77	Differential Time Course of Cytochrome P450 2D6 Enzyme Inhibition by Fluoxetine, Sertraline, and Paroxetine in Healthy Volunteers. Journal of Clinical Psychopharmacology, 2002, 22, 169-173.	1.4	70
78	Hypotension and Bradycardia in a Healthy Volunteer following a Single 5 mg Dose of Olanzapine. Journal of Clinical Pharmacology, 2002, 42, 104-106.	2.0	25
79	Î²2-Agonist Eutomers. Treatments in Respiratory Medicine, 2002, 1, 305-311.	1.2	7
80	In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sciences, 2002, 71, 163-169.	4.3	235
81	Validation and application of a sensitive assay for butorphanol in human plasma by high-performance liquid chromatography with tandem mass spectrometry detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 775, 57-62.	2.3	5
82	The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clinical Pharmacology and Therapeutics, 2002, 71, 30-38.	4.7	36
83	The Pharmacokinetics of Levosalbutamol. Clinical Pharmacokinetics, 2001, 40, 23-40.	3.5	64
84	A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. British Journal of Clinical Pharmacology, 2001, 51, 350-354.	2.4	20
85	In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. Human Psychopharmacology, 2001, 16, 541-544.	1.5	44
86	Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clinical Pharmacology and Therapeutics, 2001, 70, 48-57.	4.7	65
87	Single-Dose Pharmacokinetics of Methylphenidate in CYP2D6 Extensive and Poor Metabolizers. Journal of Clinical Psychopharmacology, 2000, 20, 347-349.	1.4	42
88	Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. International Journal of Neuropsychopharmacology, 1999, 2, 17-23.	2.1	24
89	Formulation and evaluation of a propanidid hydroxypropyl-Î²-cyclodextrin solution for intravenous anaesthesia. International Journal of Pharmaceutics, 1997, 159, 191-196.	5.2	8
90	Transplacental distribution of salbutamol enantiomers at Caesarian section. British Journal of Clinical Pharmacology, 1997, 44, 587-590.	2.4	8

#	Article	IF	Citations
91	Stability of an extemporaneously compounded levothyroxine sodium oral liquid. American Journal of Health-System Pharmacy, 1996, 53, 1157-1161.	1.0	19
92	Enantioselective disposition of albuterol in humans. Clinical Reviews in Allergy and Immunology, 1996, 14, 115-138.	6.5	32
93	Interaction of Î²2-adrenoceptor agonists with native cyclodextrins: Application to the development of chiral assays for terbutaline. Pharmaceutica Acta Helvetiae, 1996, 71, 293-296.	1.2	2
94	Stability of Hydrocortisone Oral Suspensions Prepared from Tablets and Powder. Annals of Pharmacotherapy, 1995, 29, 987-990.	1.9	14